Amphastar Pharmaceuticals, Inc. (AMPH) — Institutional Holders, Q2 2026 (page 3)

213 institutional investment managers reported a AMPH position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $571.3M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 201 to 213. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

AMPH 13F holders ranked 201–213 of 213

Institutional investors reporting a position in Amphastar Pharmaceuticals, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Torren Management#201 · 15 sh$303.000.0%
GILPIN WEALTH MANAGEMENT#202 · 8 sh$162.00+60.0%
Rockefeller Capital Management L.P.#203 · 7 sh$141.00-94.4%
JFS WEALTH ADVISORS#204 · 6 sh$122.00New
SJS Investment Consulting#205 · 6 sh$122.00New
JPL Wealth Management#206 · 5 sh$101.00New
Abound Wealth Management#207 · 4 sh$81.000.0%
Davis Capital Management#208 · 2 sh$40.00New
Hughes Financial Services#209 · 1 sh$20.00New
Capital Advisors, Ltd.#210 · 24 sh$0.00-85.9%
Evolution Advisers#211 · 4 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#212 · 36,151 sh—+27.7%
Elequin Securities#213 · 11 sh—+57.1%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.